Member Login
Search

LUGPA Policy Alert – White House Announces Nine Additional MFN Drug Pricing Agreements

September 2026

At a Glance

The White House announced nine additional agreements with pharmaceutical manufacturers under the Administration’s Most-Favored-Nation (MFN) drug pricing initiative: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. The agreements bring the total number of manufacturers with announced MFN agreements to 26, according to the White House.

The Administration says the agreements will lower prices for medicines treating conditions including cancer, glaucoma, macular degeneration, hemophilia, Parkinson’s disease, and other chronic and rare diseases. It also states that all state Medicaid programs will have access to MFN prices on covered products.

For LUGPA members, the key question is how MFN pricing will affect specific urologic therapies, physician acquisition costs, Medicare reimbursement, and patient access. The announcement does not yet provide enough product-level detail to determine those impacts.

Why It Matters for LUGPA

The White House says the 26 agreements now cover 89% of the branded drug market and could generate $600 billion in savings over the next decade. Participating manufacturers have also committed to at least $19.6 billion in near-term U.S. manufacturing investment.

For independent practices, lower drug prices could improve patient affordability and reduce acquisition costs. However, changes in acquisition costs without corresponding changes in reimbursement could affect the economics of physician-administered therapies and practice stability.

Several participating manufacturers have specialty portfolios relevant to urologic care. Astellas, in particular, has a significant oncology portfolio. However, the White House has not yet identified all affected products, pricing methodologies, or reimbursement mechanisms.

What LUGPA Is Watching

LUGPA will monitor:

  • Specific drugs and indications covered by each agreement;
  • How MFN prices will be calculated and implemented;
  • Effects on Medicare Part B and other reimbursement methodologies;
  • Changes in physician acquisition costs and reimbursement;
  • Impact on patient affordability and access;
  • Potential effects on drug availability and supply chains; and
  • Unintended consequences for independent practices and physician-administered therapies.

Looking Ahead

The nine new agreements represent a significant expansion of the Administration’s MFN initiative. For LUGPA members, the ultimate impact will depend on how these agreements translate into actual drug prices, coverage policies, reimbursement, and acquisition costs.

LUGPA will continue monitoring implementation and advocate for policies that lower costs for patients while preserving access to high-quality, physician-led urologic care and the financial stability of independent practices.

You can read the White House announcement here: White House Fact Sheet on the Nine Additional MFN Agreements